PHARM.AS AMS
Pharming Group N.V.
1W: -6.2%
1M: -10.6%
3M: -30.4%
YTD: -36.5%
1Y: -30.4%
3Y: -25.0%
5Y: +4.7%
€0.87 ($0.98)
-0.02 (-1.76%)
Weekly Expected Move ±4.6%
€1
€1
€1
€1
€1
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$333M
+16.2% ▲
5Y CAGR: +7.9%
Gross Profit
$293M
+26.4% ▲
5Y CAGR: +7.6%
Operating Income
$17M
+605.1% ▲
5Y CAGR: -26.9%
Net Income
$3M
+123.7% ▲
5Y CAGR: -41.8%
EPS (Diluted)
$0.00
+122.7% ▲
5Y CAGR: -39.7%
EBITDA
$27M
+105.3% ▲
5Y CAGR: -21.7%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $190M | $206M | $245M | $287M | $333M |
| YoY Growth | -16.9% | +8.3% | +19.3% | +16.9% | +16.2% |
| Cost of Revenue | $20M | $18M | $25M | $43M | $40M |
| Gross Profit | $170M | $188M | $220M | $232M | $293M |
| Gross Margin | 89.4% | 91.5% | 89.7% | 80.8% | 87.9% |
| R&D Expenses | $67M | $53M | $69M | $73M | $89M |
| SG&A Expenses | $92M | $132M | $88M | $162M | $187M |
| Operating Expenses | $157M | $170M | $225M | $235M | $276M |
| Operating Income | $28M | $18M | -$5M | -$3M | $17M |
| Operating Margin | 14.7% | 8.9% | -2.0% | -1.2% | 5.1% |
| Interest Expense | $6M | $5M | $6M | $9M | $16M |
| Income Before Tax | $22M | $15M | -$12M | -$8M | $11M |
| Tax Expense | $7M | $1M | -$1M | $2M | $9M |
| Net Income | $16M | $14M | -$11M | -$11M | $3M |
| Net Margin | 8.4% | 6.7% | -4.3% | -3.7% | 0.8% |
| EPS (Diluted) | $0.02 | $0.02 | $-0.01 | $-0.02 | $0.00 |
| EBITDA | $49M | $34M | $10M | $13M | $27M |
| Shares Outstanding | 876M | 884M | 843M | 689M | 722M |